The ENHANCE Phase 3b clinical trial is evaluating the safety and efficacy of a modified treatment regimen of Briumvi for ...

MS patients in the U.S. with Medicaid coverage have worse disease outcomes compared with those who have private insurance, a ...

The CAR T-cell therapy KYV-101 is safe, and showed preliminary signs of efficacy in patients with progressive forms of MS in ...

Balance issues with MS make it difficult for columnist Leigh Anne Nelson to navigate stairs and aisles at stadium events.

Frexalimab was well tolerated and maintained disease control over two years in adults with relapsing MS in an open-label ...

Over five years, relapsing-remitting multiple sclerosis patients in France taking Tysabri have adopted more at-home dosing, a review found.

The Phase 4 ENABLE study is set to be first in the U.S. to collect real-world safety and efficacy data of Briumvi for ...

Treatment with CNM-Au8 led to clinical improvements in relapsing-remitting MS patients that linked to signs of nerve cell ...

Pain is challenging, but it doesn't have to define your life. Episode 2 of Get Tough on Multiple Sclerosis offers practical ...

Tolebrutinib was found to delay disability progression in people with nonrelapsing secondary progressive MS in a Phase 3 ...

Getting used to living with MS is like trying to cook in a kitchen that's unfamiliar, columnist Ben Hofmeister writes.